Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for Israeli Healthcare Professionals only

      Confrences Baners

      AAN (American Academy of Neurology) April 2-7 2022 UBRELVY PUBLISHED ABSTRACTS

      Within-Person Analysis of Ubrogepant Treatment of Mild Versus Moderate-Severe Headache Pain during a Phase 3 Long-Term Safety Extension Trial

      Read More

      Real-World Effectiveness of Ubrogepant Among Participants With Prior Treatment Failure: Subgroup Analysis From the UNIVERSE Study

      Read More

      Real-World Effectiveness of Ubrogepant for the Acute Treatment of Migraine When Used in Combination With an Anti-Calcitonin Gene–Related Peptide Monoclonal Antibody Preventive: Results From the COURAGE Study

      Read More

      For more information please contact us, and our team will answer your questions

      Contact Us

      IL-UBR-220001 | September 2022